Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia
Hypoglycemia
About this trial
This is an interventional treatment trial for Hypoglycemia focused on measuring Hypoglycemia, Type 1 diabetes
Eligibility Criteria
Inclusion Criteria:
- type 1 diabetes (well controlled, 2-3 hypoglycemic episodes/wk) age 18-55, BMI 18-35
Exclusion Criteria:
- pregnancy
- significant diabetes complications
- liver disease, cirrhosis
- cardiac disease
- neurological disorder
- autonomic neuropathy
- kidney disease
- lactose intolerance
Sites / Locations
- Yale School of Medicine
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Naltrexone (higher dose)
Naltrexone (lower dose)
Naltrexone 100mg tablets were randomly given on 1 of 2 occassions (the other was placebo). The drug was administered 12 hours and 1 hour orally pre-procedure to participants. Placebo was given to the high dose group on 1 of their 2 visits- the order in which placebo was given was randomized by dosage arm.
Naltrexone 50mg tablets were randomly given on 1 of 2 occassions (the other was placebo). The drug was administered 12 hours and 1 hour orally pre-procedure to participants. Placebo was given to the low dose group on 1 of their 2 visits- the order in which placebo was given was randomized by dosage arm.